Massivemarkets

MRNA

Moderna, Inc. Common Stock

Nasdaq · usd

$193.09-9.54 (-4.71%)
As of 9:19:26 AM EDT on Oct 23, 2026 · 15-minute delayed

Moderna, Inc. Common Stock (MRNA) trades at $193.09 (-4.71%) as of 9:19:26 AM EDT on Oct 23, 2026, +11.27% over the past month. Market cap is $80.9B, with 1.8 days to cover in short interest.

Stock performance

How Moderna, Inc. Common Stock (MRNA) stock has performed from one day to one year, with its 52-week range.

-2.15%
-$4.25 over 1D
$190.94$192.92$194.91$196.894:00 AM5:20 AM6:40 AM7:55 AM9:15 AM$193.01
1D
-17.57%
1W
-14.32%
1M
+11.27%
YTD
+587.11%
1Y
+657.78%
52-wk range
$22.28 – $254.48

Key statistics

Today's trading snapshot for MRNA: day range, open, previous close, volume and market cap.

Day range
$180.80 – $241.26
Open
$240.13
Prev close
$202.63
Volume
50M
Market cap
$80.9B
Shares out
399.24M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Moderna, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
36.31
P/B
11.97
P/FCF
—
ROE
-46.6%
ROA
-28.7%
Debt/Equity
0.09
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events Moderna, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Executive leadershipSep 30, 2026

    In addition, subject to the Compensation Committee's approval, Mr. Andres will be eligible to participate in the Company's annual equity award program in future years. The target value for this annual equity award will be $4,000,000 to $5,000,000, subject to adjustment by the Compensation Committee.

  • Equity activitySep 1, 2026

    The Company relied on these exemptions from registration based in part on representations made by the initial purchasers in the purchase agreement dated August 27, 2026 by and among the Company and the representatives of the initial purchasers.

  • Board of directorsJul 8, 2026

    On July 6, 2026, the Board of Directors (the "Board") of Moderna, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee"), appointed Michael McDonnell to the Board, effective July 8, 2026. Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025.

  • Governance documentsMay 11, 2026

    On May 6, 2026, the Board of Directors (the "Board") of Moderna, Inc. (the "Company") approved an amendment to the Company's Second Amended and Restated By-Laws (the "By-Law Amendment"), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.

  • Material agreementsMar 5, 2026

    Moderna, Inc. (the "Company") and ModernaTX, Inc. (together with the Company, "Moderna") and Arbutus Biopharma Corporation ("Arbutus"), Genevant Sciences GmbH ("Genevant" and, together with Arbutus, "Arbutus/Genevant"), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the "Settlement Agreement") to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the "Litigation").

Dividend history and stock splits

Moderna, Inc. Common Stock's recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-10Aug 3, 2017
  • 1-for-10Dec 23, 2011
  • 1-for-4Jul 22, 2010

MRNA short interest

How heavily MRNA is shorted: shares short, days to cover and average daily volume.

Days to cover
1.8
Short interest
30.86M
Avg volume
16.89M

As of · reported to FINRA twice monthly.

MRNA news

The latest news and headlines about Moderna, Inc. Common Stock (MRNA).

Frequently asked questions

What is the Moderna, Inc. Common Stock (MRNA) stock price today?

Moderna, Inc. Common Stock (MRNA) is trading at $193.09 (-4.71% on the day) as of 9:19:26 AM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Moderna, Inc. Common Stock?

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020.

What is the short interest in MRNA?

As of Sep 30, 2026, MRNA has 30.86M shares short and 1.8 days to cover.

What exchange is MRNA listed on?

Moderna, Inc. Common Stock (MRNA) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of MRNA with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MRNA analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.